Virtus LifeSci Biotech Clinical Trials ETF (BBC)
| Assets | $15.15M |
| Expense Ratio | 0.79% |
| PE Ratio | n/a |
| Shares Out | 650,004 |
| Dividend (ttm) | $0.24 |
| Dividend Yield | 1.12% |
| Ex-Dividend Date | Dec 20, 2024 |
| Payout Frequency | n/a |
| Payout Ratio | n/a |
| Volume | 29,670 |
| Open | 21.23 |
| Previous Close | 21.66 |
| Day's Range | 21.18 - 21.57 |
| 52-Week Low | 13.42 |
| 52-Week High | 31.65 |
| Beta | 0.96 |
| Holdings | 117 |
| Inception Date | Dec 16, 2014 |
About BBC
Fund Home PageThe Virtus LifeSci Biotech Clinical Trials ETF (BBC) is an exchange-traded fund that mostly invests in health care equity. The fund tracks an equally weighted index of US-listed biotech companies with lead drugs in various phases of clinical trials. BBC was launched on Dec 16, 2014 and is issued by Virtus Investment Partners.
Top 10 Holdings
12.86% of assets| Name | Symbol | Weight |
|---|---|---|
| Celcuity Inc. | CELC | 2.51% |
| Sana Biotechnology, Inc. | SANA | 1.28% |
| Cogent Biosciences, Inc. | COGT | 1.27% |
| Terns Pharmaceuticals, Inc. | TERN | 1.19% |
| Centessa Pharmaceuticals plc | CNTA | 1.15% |
| AbCellera Biologics Inc. | ABCL | 1.14% |
| Intellia Therapeutics, Inc. | NTLA | 1.12% |
| Prothena Corporation plc | PRTA | 1.09% |
| Upstream Bio, Inc. | UPB | 1.06% |
| Summit Therapeutics Inc. | SMMT | 1.05% |
Dividends
| Ex-Dividend | Amount | Pay Date |
|---|---|---|
| Dec 20, 2024 | $0.23947 | Dec 27, 2024 |
| Dec 20, 2023 | $0.0823 | Dec 29, 2023 |
| Dec 20, 2017 | $0.29724 | Dec 27, 2017 |
| Dec 21, 2015 | $0.14733 | Dec 29, 2015 |
Performance
BBC had a total return of -24.93% in the past year, including dividends. Since the fund's inception, the average annual return has been -1.24%.
News
Seeking Stocks With Vitality In The Volatile Healthcare Sector
Investors cooled to the healthcare sector in 2024, which dramatically trailed global and US equity markets for the year. any investors are now asking: how will the policy changes under a new US admini...
What The Inflation Reduction Act Means For Drug Prices
The recently enacted Inflation Reduction Act looks to rein in prescription drug prices and could impact the pharma industry's long-term financial performance. The legislation caps out-of-pocket costs ...
Should Investors Follow Private Equity into Life Sciences?
Reflecting what it considers the vast potential of life sciences companies, Bain Capital is making another huge bet on the industry. The Boston-based investment firm has raised $1.9 billion in a new f...
Moving Beyond COVID In Biopharma
Just over one year after COVID-19 disrupted our lives, we are now getting to the point where multiple vaccine options are nearly ubiquitous for those in the United States. Per the CDC, as of April 12,...
Novavax's 30% surge boosts biotech ETFs to best day in weeks
Exchange-traded funds with exposure to biotech stocks rocketed higher Tuesday on hopeful news about treatments for COVID-19.
3 ETFs With Q2 Gains Of At Least 30%
The S&P 500 is sitting on an impressive 16.36% gain with just one day left in the second quarter.
3 Biotech ETFs Up 10% Or More Over The Last Month
Something's been brewing in the health care sector, the second-largest group in the S&P 500.
Failure to Launch: The ETF Built to Fight the Coronavirus That Never Came to Be
Bloomberg's Eric Balchunas and Scarlet Fu break down the Virtus LifeSci Biotech Clinical Trials ETF (ticker: BBC) with Paul Yook, CIO of LifeSci Venture Partners.
Best Growth ETFs for Q1 2020
The best Growth ETFs for Q1 2020 are XLK, BBC, and VGT.
Best Healthcare ETFs for Q1 2020
The best Healthcare ETFs for Q1 2020 are BBC, SBIO, and KURE.
5 Best ETFs Of 2019
With just two trading days left in 2019, the SPDR S&P 500 ETF, the world's largest exchange traded fund, is higher by 29.19% this year, meaning the S&P 500 is on pace for its best annual performance s...
There's A Really Good Chance You Missed One Of The Year's Best ETFs
Investors have been piling into exchange traded funds again this year, mostly pure beta, core equity and fixed income funds.